Mike Lynch-backed Darktrace accused of misrepresenting accounts by short seller
Cybersecurity company allegedly engages in ‘channel stuffing’ to inflate sales figures
Source: telegraph.co.uk
Page 44 - Cassava Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Cassava Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Cassava Sciences Today - Breaking & Trending Today
Cassava Sciences (SAVA) Stock: Data For Mild Alzheimer's Good Risk/Reward Profile
Cassava Sciences released data for over 200 patients in an open-label trial at 12 months. The mild AD subgroup performed unprecedentedly. See the outlook here.
Source: seekingalpha.com
Cassava Sciences, Inc. Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
Cassava Sciences, Inc. announced positive top-line Phase 2 results for simufilam, its oral drug candidate for Alzheimer's disease dementia. This was an open-label safety study with exploratory... | January 25, 2023
Source: marketscreener.com
Alzheimer's Disease Therapeutics Market Report Research 2022: Increasing Gap of Unmet Need of Effective Therapeutics
/PRNewswire/ -- The "Alzheimer's Disease Therapeutics (2022 Edition) - Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of...
Source: prnewswire.com
Is a Short Squeeze Coming in Cassava Sciences (SAVA) Stock?
Today, a rally across most meme stocks has investors looking at Cassava Sciences and SAVA stock due to the short interest in this stock.
Source: investorplace.com